Therapeutic Solutions International(TSOI)
$0.000.00 (0.00%)
TSOI
Therapeutic Solutions International financials statements
$0.00
At close:0.00 (0.00%)
Therapeutic Solutions International (TSOI) Ratios
65 Followers
Therapeutic Solutions International Ratios
TSOI's free cash flow for Q3 2024 was $70.84K. For the 2024 fiscal year, TSOI's free cash flow was increased by $0.00 and operating cash flow was $70.84K. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.05 | 0.14 | 0.45 | 0.15 | 0.06 |
| Quick Ratio | 0.03 | 0.12 | 0.43 | 0.15 | 0.06 |
| Cash Ratio | 0.01 | 0.01 | 0.04 | 0.11 | 0.01 |
| Solvency Ratio | -0.92 | -1.61 | -1.17 | -0.92 | -0.72 |
| Operating Cash Flow Ratio | -0.56 | -0.46 | -0.29 | -0.28 | -0.13 |
| Short-Term Operating Cash Flow Coverage | -1.39 | -0.96 | -0.69 | -0.68 | -0.32 |
| Net Current Asset Value | $ -1.92M | $ -1.91M | $ -1.40M | $ -2.03M | $ -2.21M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.30 | 0.64 | 1.72 | 3.16 |
| Debt-to-Equity Ratio | 0.79 | 0.88 | -1.36 | -0.59 | -0.48 |
| Debt-to-Capital Ratio | 0.44 | 0.47 | 3.75 | -1.41 | -0.93 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.01 | -0.02 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.93 | 2.95 | -2.13 | -0.34 | -0.15 |
| Debt Service Coverage Ratio | -1.26 | -1.75 | -1.40 | -1.47 | -1.01 |
| Interest Coverage Ratio | -4.69 | -5.08 | -3.77 | -6.11 | -2.97 |
| Debt to Market Cap | 0.24 | 0.07 | 0.02 | 0.08 | 0.23 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.58 | -0.35 | -0.43 | -0.42 | -0.71 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.86% | 61.58% | 70.85% | 79.59% | 89.03% |
| EBIT Margin | -1817.47% | -1562.32% | -1609.29% | -3027.11% | -4897.54% |
| EBITDA Margin | -1502.53% | -1444.01% | -1596.91% | -3015.97% | -4873.57% |
| Operating Profit Margin | -2006.67% | -1586.03% | -1578.79% | -2950.78% | -3794.02% |
| Pretax Profit Margin | -2245.04% | -1874.80% | -2028.45% | -3509.68% | -6173.20% |
| Net Profit Margin | -2191.86% | -1844.58% | -2029.00% | -3509.68% | -6173.20% |
| Continuous Operations Profit Margin | -2247.31% | -1875.57% | -2029.00% | -3509.68% | -6173.20% |
| Net Income Per EBT | 97.63% | 98.39% | 100.03% | 100.00% | 100.00% |
| EBT Per EBIT | 111.88% | 118.21% | 128.48% | 118.94% | 162.71% |
| Return on Assets (ROA) | -65.91% | -105.78% | -172.60% | -364.54% | -545.76% |
| Return on Equity (ROE) | -192.82% | -312.18% | 367.89% | 123.72% | 83.40% |
| Return on Capital Employed (ROCE) | -142.66% | -235.03% | 295.19% | 106.06% | 51.26% |
| Return on Invested Capital (ROIC) | -91.55% | -133.18% | -785.89% | 250.73% | 99.56% |
| Return on Tangible Assets | -367.80% | -632.95% | -186.64% | -475.03% | -1034.71% |
| Earnings Yield | -68.47% | -25.14% | -4.51% | -17.87% | -40.05% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.16 | 8.14 | 8.79 | 25.68 | 9.47 |
| Payables Turnover | 0.09 | 0.19 | 0.11 | 0.04 | 0.01 |
| Inventory Turnover | 1.63 | 1.87 | 1.07 | 2.37 | 0.58 |
| Fixed Asset Turnover | 0.20 | 0.73 | 0.46 | 0.98 | 4.89 |
| Asset Turnover | 0.03 | 0.06 | 0.09 | 0.10 | 0.09 |
| Working Capital Turnover Ratio | -0.05 | -0.13 | -0.09 | -0.03 | -0.01 |
| Cash Conversion Cycle | -3724.40 | -1640.36 | -3081.42 | -8668.17 | -38671.55 |
| Days of Sales Outstanding | 70.78 | 44.83 | 41.55 | 14.21 | 38.55 |
| Days of Inventory Outstanding | 224.09 | 194.94 | 341.60 | 154.05 | 627.10 |
| Days of Payables Outstanding | 4019.27 | 1880.14 | 3464.57 | 8836.44 | 39337.19 |
| Operating Cycle | 294.87 | 239.78 | 383.15 | 168.27 | 665.65 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -65.31 | 0.00 | -2.76 | -121.71 | 0.00 |
| Capital Expenditure Coverage Ratio | -65.31 | 0.00 | -2.76 | -121.71 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.19 | -0.94 | -0.65 | -0.64 | -0.32 |
| Operating Cash Flow to Sales Ratio | -10.66 | -4.92 | -4.93 | -10.58 | -11.30 |
| Free Cash Flow Yield | -33.81% | -6.71% | -1.49% | -5.43% | -7.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.46 | -3.98 | -22.16 | -5.60 | -2.50 |
| Price-to-Sales (P/S) Ratio | 32.01 | 73.36 | 449.66 | 196.43 | 154.13 |
| Price-to-Book (P/B) Ratio | 2.82 | 12.42 | -81.53 | -6.92 | -2.08 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.96 | -14.90 | -67.01 | -18.42 | -13.64 |
| Price-to-Operating Cash Flow Ratio | -3.00 | -14.90 | -91.29 | -18.57 | -13.64 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | -0.26 | -2.66 | 0.22 | 0.10 |
| Enterprise Value Multiple | -2.71 | -5.44 | -28.59 | -6.93 | -3.88 |
| Enterprise Value | 4.03M | 16.23M | 66.63M | 13.10M | 5.19M |
| EV to EBITDA | -2.71 | -5.44 | -28.59 | -6.93 | -3.88 |
| EV to Sales | 40.70 | 78.48 | 456.54 | 209.00 | 188.87 |
| EV to Free Cash Flow | -3.76 | -15.94 | -68.03 | -19.60 | -16.71 |
| EV to Operating Cash Flow | -3.82 | -15.94 | -92.69 | -19.76 | -16.71 |
| Tangible Book Value Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 0.98 | 0.98 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.24 | 1.20 | 1.26 | 1.16 | 1.26 |
| Research & Development to Revenue | 5.66 | 6.97 | 5.45 | 8.97 | 1.01 |
| SG&A to Revenue | 10.65 | 8.54 | 11.05 | 21.34 | 37.82 |
| Stock-Based Compensation to Revenue | 4.00 | 7.95 | 9.17 | 18.60 | 17.02 |
| Income Quality | 0.49 | 0.28 | 0.24 | 0.30 | 0.18 |
Currency in USD

